Bladder Disorders Clinical Trials

A listing of Bladder Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 345 clinical trials
Featured trial
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC, ovarian cancer, CRPC, TNBC, bladder …

cancer
measurable disease
bladder tumor
cancer of the ovary
  • 36 views
  • 11 Jul, 2022
  • 19 locations
Featured trial
If you are dealing with overactive bladder (OAB) symptoms you may be eligible to participate in a research study for OAB.

If you are dealing with overactive bladder (OAB) symptoms you may be eligible to participate in a research study for OAB.

  • 286 views
  • 08 Nov, 2020
  • 1 location
Featured trial
SYNERGY

SYNERGY

  • 99 views
  • 08 Nov, 2020
  • 1 location
A Phase 3, Double-blind, Randomized, Multicenter, Parallel Group, Placebo-controlled Sequential Dose Titration Study to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Pediatric Subjects From 5 to < 18 Years of Age With Overactive Bladder (Dolphin)

The purpose of this study is to evaluate the efficacy of mirabegron in children (5 to < 12 years of age) with OAB. This study will also evaluate the safety and tolerability of mirabegron in pediatric participants with OAB and evaluate the pharmacokinetics after multiple dose administration of mirabegron in …

mirabegron
incontinence
  • 9 views
  • 14 Sep, 2022
  • 27 locations
A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

This study will evaluate the efficacy and safety of DA-8010 in patients with overactive bladder.

solifenacin
  • 1 views
  • 19 Jun, 2022
  • 1 location
A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.

invasive bladder cancer
gemcitabine
fluorouracil
cancer
mitomycin
  • 78 views
  • 18 Sep, 2022
  • 100 locations
A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions

The purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator's Choice, for participants with high-risk non-muscle-invasive bladder cancer (NMIBC) who harbor fibroblast growth factor receptor (FGFR) mutations or fusions, and who recurred after bacillus calmette-guerin (BCG) therapy.

invasive bladder cancer
cancer
growth factor
human chorionic gonadotropin
bcg vaccine
  • 0 views
  • 20 Sep, 2022
  • 143 locations
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease.

radical cystectomy
intravesical bcg
invasive bladder cancer
cystoscopy
transurethral resection
  • 11 views
  • 15 Sep, 2022
  • 101 locations
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy (SunRISe-2)

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy.

radical cystectomy
gilbert's syndrome
conjugated bilirubin
invasive bladder cancer
bladder tumor
  • 66 views
  • 16 Sep, 2022
  • 149 locations
InterStim Micro Post Market Clinical Follow-up Study (ELITE)

Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the InterStim Micro System for sacral neuromodulation.

incontinence
neuromodulation
  • 0 views
  • 30 Jun, 2022
  • 27 locations